Top Health-care stocks:
Health-care shares were flat in pre-market trade Wednesday.
In health-care stocks news, Amicus Therapeutics ( FOLD ) soared 21% pre-market on reported positive 18-month data from its second Phase 3 study of the oral small molecule chaperone migalastat HCl in Fabry disease patients with amenable mutations.
The study compared oral migalastat to standard-of-care enzyme replacement therapies (ERTs) for Fabry disease, Fabrazyme and Replagal. The co-primary outcome measures were the mean annualized changes in estimated glomerular filtration rate (eGFR) and measured (iohexol) GFR (mGFR) assessed by descriptive comparisons of migalastat and ERT over 18 months.
And, Evogene ( EVGN ), a plant-genomics company specializing in crop productivity, Wednesday reported a Q2 loss that widened more than expected from the year-earlier period as revenue fell and expenses rose.
It posted a Q2 net loss of $3.2 million, or $0.13 per share, compared with a year-earlier loss of $1.9 million, or $0.10 per share. On average, three analysts polled by Capital IQ were predicting a loss of $0.12 per share.
Total revenue declined 11% to $3.9 million, slightly below the $4.1 million estimate of one analyst.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.